Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc.
Your view on HRMY
Overview
What the company does, where it operates, and who runs it.
About Harmony Biosciences Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeffrey M. Dayno
- Headquarters
- 630 West Germantown Pike, Plymouth Meeting, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jeffrey M. Dayno
- Headquarters
- 630 West Germantown Pike, Plymouth Meeting, PA, US
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Harmony Biosciences Holdings, Inc., and the rating behind it. HRMY last traded at $41.52, 13.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Harmony Biosciences Holdings, Inc.. Starting points for Harmony Biosciences Holdings, Inc.: P/E 13.3, EPS $3.13, beta 0.93 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Harmony Biosciences Holdings, Inc.. Harmony Biosciences Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Harmony Biosciences Holdings, Inc.. Trailing twelve-month EPS for Harmony Biosciences Holdings, Inc. stands at $3.13. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Harmony Biosciences Holdings, Inc.. Harmony Biosciences Holdings, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Harmony Biosciences Holdings, Inc. valued side by side against its closest peers. Harmony Biosciences Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Harmony Biosciences Holdings, Inc., and how their positions are changing. At a $2.40B market value, institutional positions materially move Harmony Biosciences Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Harmony Biosciences Holdings, Inc. executives and directors. Shares of Harmony Biosciences Holdings, Inc. have traded between $25.52 and $40.93 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Harmony Biosciences Holdings, Inc.. Harmony Biosciences Holdings, Inc. is a $2.40B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Harmony Biosciences Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Harmony Biosciences Holdings, Inc.. Coverage tracks Harmony Biosciences Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.